GAU 1633

Dkt.50875-F-PCT-US/JPW/SHS/MVM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: Graham P. Allaway et al.

JAN 25 2001

Serial No.:

09/460,216

Group Art Unit: 1633

TECH CENTER 1600mg

Filed

December 13, 1999

For

METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+

1185 Avenue of the Americas

New York, New York January 19, 2001

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the PTO-1449 form attached hereto as **Exhibit A.**

- 1. U.S. Patent No. 5,021,409 issued June 4, 1991 to Murrer et al.;
- 2. U.S. Patent No. 5,126,433, issued 6/30/92 to Maddon et al.;
- 3. U.S. Patent No. 5,440,021, issued August 5, 1995 to Chuntharapai et al.;
- 4. U.S. Patent No. 5,504,003, issued April 2, 1996 to Li et al.;
- 5. Alkhatib, G., et al., (1996), CC CKR5: A RANTES, MIP-1 α , MIP-1 β Receptor As A Fusion Cofactor For Macrophage-tropic HIV-1, Science 272: 1955-1958;
- 6. Alkhatib et al., (1997), HIV-1 Coreceptor Activity Of CCR5

Graham P. Allaway et al.

Serial No.:

09/460,216

Filed Page 2 December 13, 1999

And Its Inhibition By Chemokines: Independence From G Protein Signaling And Importance Of Coreceptor Downmodulation, <u>Virology</u> 234: 340-348 (Exhibit 1);

- 7. Arenzana-Selsdedos, F., et al., (1996), HIV Blocked By Chemokine Antagonist, Nature 383: 400;
- 8. Berger et al., (1999), Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism, And Disease, Ann. Rev. Immunol. 17: 657-700 (Exhibit 2);
- 9. Bleul, C.C., et al., (1996), The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry, Nature 382: 829-832;
- 10. Brenner, T.J., et al., (1991), Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children, The Lancet 337: 1001-1003;
- 11. Choe, H., et al., (1996), The β -chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates, Cell 85: 1135-1148;
- 12. Cocchi, F., et al., (1995), Identification Of RANTES, MIP- 1α , And MIP- 1β As The Major HIV-suppressive Factors Produced By CD8[†] T Cells, Science 270: 1811-1815;
- 13. Daar et al., (1990), High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type 1 Isolates, <u>Proc. Nat. Acad. Sci. USA</u> 87: 6574-6578;
- 14. DeClercq, E., et al., (1992), Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 And HIV-

Applicants: Graham P. Allaway et al.

Serial No.: 09/460,216

Filed: December 13, 1999

Page 3

2 Replication By A Class Of Bicyclams Interacting With A Virus Uncoating Event, Proc.Natl.Acad.Sci. 89: 5286-5290;

- 15. DeClercq, E., et al., (1994), Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Derivative JM3100, Antimicrobial Agents and Chemotherapy 38: 668-674;
- 16. DeClerq, E., (1995), Antiviral Therapy For Human Immunodeficiency Virus Infections, <u>J. Clin. Microbiol. Rev.</u> 8(2): 200-239 (Exhibit 3);
- 17. Deng et al., (1996), Identification Of A Major Co-receptor For Primary Isolates Of HIV-1, Nature 381: 661-666;
- 18. Doranz et al., (1996), A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And The β -Chemokine Receptors CKR-5, CKR-3, and CKR-2b As Fusin Cofactors, Cell 85: 1149-1158 (Exhibit 4);
- 19. Doranz et al., (1997), A Small-Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Coreceptor, <u>J. Exp. Med.</u> 186(8): 1395-1400 (Exhibit 5);
- 20. Dragic, T., et al., (1996), HIV-1 Entry Into CD4+ Cells Is Mediated By The Chemokine Receptor CC-CKR-5, <u>Nature</u> 381: 667-673;
- 21. Fahey et al., (1992), Status Of Immune-based Therapies In HIV Infection And AIDS, Clin. Exp. Immunol. 88: 1-5;
- 22. Feng et al, (1996), HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-transmembrane, G Protein-coupled

Applicants: Graham P. Allaway et al.

Serial No.: 09/460,216

Filed: December 13, 1999

Page 4

Receptor, Science 272: 872-877;

- 23. Fox, J.L., (1994), No Winners Against AIDS, <u>Bio/Technology</u> 12: 128;
- 24. Gong, J., et al., (1995), Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH_2 -terminal Residues, <u>J. Exp. Med.</u> 181: 631-640;
- 25. Gong, J., et al., (1996), RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors, <u>J.Biol.Chem.</u> 271:10521-10527;
- 26. Hattori, T., et al., (1989), Involvement Of Tryptaserelated Cellular Protease(s) In Human Immunodeficiency Virus Type 1 Infection, <u>FEBS Letters</u> 248: 48-52;
- 27. Haynes et al., (1996), Update On The Issues Of HIV Vaccine Development, Ann. Med. 28: 39-41;
- 28. Jones, S.A., et al., (1997), Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors, <u>J. Biol.</u>
 Chem. 272: 16166-16169;
- 29. Klotman et al., (1995), Transgenic Models Of HIV-1, <u>AIDS</u> 9(4): 313-324 (Exhibit 6);
- 30. Levy, (1996), Controlling HIV Pathogenesis: The Role Of The Noncytotoxic Anti-HIV Response Of CD8+ T Cells, Immunology Today 17: 217-224 (Exhibit 7);
- 31. Litwin et al., (1996), Human Immunodeficiency Virus Type 1
 Membrane Fusin Mediated By A Laboratory-adapted Strain And
 A Primary Isolate Analyzed By Resonance Energy Transfer,

Applicants: Appricants: Serial No.: Graham P. Allaway et al.

09/460,216 Filed

December 13, 1999

Page 5

J. Virol. 70(9): 6437-6441 (Exhibit 8);

- 32. McKnight, Α., et al., (1997), Inhibition Of Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is Both Cell Type And Virus Strain Dependent, <u>J. Virol.</u> 71(2): 1692-1696;
- 33. Moser, B., et al., (1993), Interleukin-8 Antagonists Generated By N-terminal Modification, J. Biol. Chem. 268: 7125-7128;
- Oberlin, E., et al., (1996), The CXC Chemokine SDF-1 Is The 34. Ligand For LESTR/Fusion And Prevents Infection By T-cellline-adapted HIV-1, Nature 382: 833-835;
- Oellerich, M., (1984), Enzyme-Immunoassay: A Review, J. 35. Clin. Chem. Clin. Biochem. 22(12): 895-904;
- 36. Raport, C.J., et al., (1996), New Members Of The Chemokine Receptor Gene Family, J. Leuk. Biol. 59: 18-23;
- (1996), Molecular Cloning Μ., et al., 37. Samson, Functional Expression Of A New Human CC-chemokine Receptor Gene, Biochemistry 35: 3362-3367 (Exhibit 9);
- Scarlatti et al., (1997), In Vivo Evolution Of HIV-1 Co-38. receptor Usage And Sensitivity To Chemokine-mediated Suppression, Nature Medicine 3(11): 1259-1265 (Exhibit 10);
- Simmons, G., et al., (1997), Potent Inhibition Of HIV-1 39. Infectivity In Macrophages And Lymphocytes By A Novel CCR5 Antagonist, Science 276: 276-279;
- Szabo et al., (1992), CD4 Changes Conformation Upon Ligand 40.

Applicants: Graham P. Allaway et al.

Applicants: Serial No.: Filed : 09/460,216

December 13, 1999

Page 6

Binding, <u>J.Immunol</u>. 149(11): 3596-3604 (Exhibit 11);

- 41. Trkola, A., et al., (1996), CD4-dependent, Antibodysensitive Interactions Between HIV-1 And Its Co-receptor CCR-5, Nature 384: 184-187;
- 42. Wells, T., et al., (1996), Selectivity And Antagonism Of Chemokine Receptors, J. Leuk. Biol. 59: 53-60;
- 43. Wu, L., et al., (1996), CD4-induced Interaction Of Primary HIV-1 gp120 Glycoproteins With The Chemokine Receptor CCR-5, Nature 384: 179-183;
- 44. Wu, L., et al., (1997), CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophage-tropic HIV-1, In Vitro, <u>J. Exp. Med.</u> 185: 1681-1691; and
- Zhang, Y,J., et al., (1994), Structure/Activity Analysis Of 45. Monocyte Chemoattractant Protein-1 (MCP-1)Human Вy Mutagenesis, J. Biol. Chem. 269: 15918-15924.

The subject application is a continuation of and claims the benefit under 35 U.S.C. §120 of PCT International Application No. PCT/US98/12331, filed June 12, 1998, which is a continuation-inpart of and claims the benefit under 35 U.S.C. §120 of U.S. 08/876,078, filed June 13, 1997, which is a Serial No. continuation-in-part of and claims the benefit under 35 U.S.C. \$120 of U.S. Serial No. 08/831,823, filed April 2, 1997.

The above listed references 3-5, 7, 9-12, 20, 24-26, 28, 32-34, 36, 39, and 41-45 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on December 21, 1998 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. Above listed references 1, and 14-15 were submitted to and considered by the

Applicants: Applicants: Serial No.: Filed : Graham P. Allaway et al.

09/460,216

Page 7

December 13, 1999

United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on January 21, 2000 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. Also, above listed references 13, 21, 23, 27 and 39 were cited by the United States Patent and Trademark Office in an Office Action dated December 21, 1998 in connection with 08/831,823, filed April 2, 1997. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

The above listed references 5, 7, 9, 11-12, 20, 24-25, 28, 32-34, 36, 39, and 41-45 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on October 8, 1998 in connection with U.S. Serial No. 08/876,078, filed June 13, 1997. Above listed references 17, 21-23, 27 and 35 were cited by the United States Patent and Trademark Office in an Office Action dated March 23, 1998 in connection with U.S. Serial No. 08/876,078, filed June 13, 1997. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

A Search Report was issued on October 15, 1998 in connection with PCT International Application No. PCT/US98/12331, filed June 12, A copy of the Search Report is attached hereto as Exhibit B. Above listed references 6, 12-13, 17, 19, 21-23, 27, 35, 38-39 and 41 were cited in the Search Report. Additionally, above listed reference 8 was cited in a Preliminary Examination Report issued January 27, 2000 in connection with PCT International

Graham P. Allaway et al.

Serial No.: 09/460,216

Filed: December 13, 1999

Page 8

Application No. PCT/US98/12331, filed June 12, 1998. A copy of the Preliminary Examination Report is attached hereto as Exhibit C. References 12, 39 and 41 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on December 21, 1998 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. 13 was cited by the United States Patent and Trademark Office in an Office Action dated December 21, 1998 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. References 17, 21-23, 27 and 35 were cited by the United States Patent and Trademark Office in an Office Action dated March 23, 1998 in connection with U.S. Serial No. 08/876,078, filed June 13, 1997. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120. References 6, 8, 19 and 38 are attached hereto as Exhibits 1, 2, 5 and 10, respectively.

The above listed references 12, 22, 24-25, 30, 33, 36-37, 42 and 45 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on March 10, 1997 in connection with U.S. Serial No. 08/663,616, filed June 14, 1996. References 12, 24-25, 33, 36, 42 and 45 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on December 21, 1998 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. Reference 22 was cited by the United States Patent and Trademark Office in an Office Action dated March 23, 1998 in connection with U.S. Serial No. 08/876,078, filed June Accordingly, under 37 C.F.R. §1.98(d) copies of 13, 1997. references 12, 22, 24-25, 33, 36, 42, and 45 are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United

Graham P. Allaway et al.

Serial No.: Filed :

09/460,216

Page 9

December 13, 1999

States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120. References 30 and 37 are attached hereto as **Exhibits 7** and **9**, respectively.

The above listed references 3, 5, 7, 9-12, 15-16, 18, 20, 24, 26, 28-29, 31-34, 36 and 39-45 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on January 4, 1999, in connection with U.S. Serial No. 08/874,618, filed June 13, 1997. Above listed references 2, 13, 17, 20-23 and 27 were cited by the United States Patent and Trademark Office in an Office Action dated September 2, 1998 in connection with U.S. Serial No. 08/874,618, filed June 13, 1997. References 3-5, 7, 9-12, 20, 24, 26, 28, 32-34, 36, 39 and 41-45 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on December 21, 1998 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. 15 was submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on January 21, 2000 in connection with U.S. Serial No. 08/831,823, filed April 2, 1997. Accordingly, under 37 C.F.R. §1.98(d) copies of references 3-5, 7, 9-12, 15, 20, 24, 26, 28, 32-34, 36, 39 and 41-45 are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120. References 16, 18, 29, 31 and 40 are attached hereto as Exhibits 3, 4, 6, 8 and 11, respectively.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Graham P. Allaway et al.

Serial No.:

09/460,216

Filed Page 10 December 13, 1999

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is deemed necessary in connection with the filing of this Information Disclosure However, if any fee is required authorization is Statement. hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. ↑20231.

John P. White

Reg. No. 28,678 Spencer H. Schneider

Reg. No. 45,923

Spencer H. Schneider Registration No. 45,923 Attorneys for Applicant(s) Cooper & Dunham, LLP 1185 Avenue of the Americas

Registration No. 28,678

New York, New York 10036

(212) 278-0400

John R. White